This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tugrul, K. Search for Related Content Social Bookmarking                         What's this?

Newer Antipsychotic Agents: Impact on Quality of Life and Alternative Applications

Inpatient Clinical Trials, in the Biological Psychiatry Program at the University of Cincinnati Medical Center in Cincinnati, Ohio

The introduction of the first antipsychotic drugs in the 1950s revolutionized treatment of mentally ill patients. Patients could be treated in the community and not confined to psychiatric institutions. However, these conventional neuroleptic agents were not ideal. Although effective for the positive symptoms of schizophrenia, they had little effect on the negative symptoms. They also had distressing side effects including extrapyramidal symptoms, anticholinergic effects, and sedation that caused many patients to discontin ue treatment. In the late 1980s the first newer antipsychotic (clozapine) became avail able. Newer antipsychotics, which antagonize both the dopamine and serotonin recep tors, are effective for both the positive and negative symptoms of psychoses and are less likely than conventional neuroleptics to cause extrapyramidal symptoms at recom mended doses. Thus the newer antipsychotics may offer patients an improved quality of life while reducing costs. Clozapine is effective in up to 40% of treatment-refractory patients and may be useful in patients with mood disorders. Risperidone may be benefi cial in some treatment-refractory patients, but results in patients with mood disorders are mixed. Further study is required to explore fully all possible applications of the newer antipsychotic drugs. (Am Psychiatr Nurses Assoc [1998]. 4, S35-S41.)

Journal of the American Psychiatric Nurses Association, Vol. 4, No. 4, S35-S41 (1998)
DOI: 10.1177/107839039800400408


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?